Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of BEMA Buprenorphine NX in Opioid Dependence
NCT01666119Phase 2Completed
- Sponsor
- BioDelivery Sciences International
- Start
- Aug 2012
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buprenorphine + naloxone in opioid use disorder (OUD), sponsored by BioDelivery Sciences International. Primary endpoint: Adverse Events at 12 weeks. Started Aug 2012; status: completed.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01666119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666119.